Bio Techne Corp Stock Today
| TECH Stock | USD 66.78 0.92 1.40% |
PerformanceFair
| Odds Of DistressLow
|
Bio Techne is trading at 66.78 as of the 8th of February 2026. This is a 1.40% increase since the beginning of the trading day. The stock's open price was 65.86. Bio Techne has only a 8 % chance of going through financial distress over the next few years but had a somewhat fair performance during the last 90 days. Note, on February 3, 2026, Representative April Delaney of US Congress acquired under $15k worth of Bio Techne Corp's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of February 1989 | Category Healthcare | Classification Health Care |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. The company has 156.45 M outstanding shares of which 10.36 M shares are at this time shorted by private and institutional investors with about 5.64 trading days to cover. More on Bio Techne Corp
Moving against Bio Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Charles Kummeth | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Techfinancials Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, Jakarta Stock Exchange, OBX Technology GR, NASDAQ Composite Total, NASDAQ Health Care, Oslo All Share, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDebt leverage enables Bio Techne to amplify potential investment gains using borrowed funds. Evaluating debt relative to total assets helps investors assess Bio Techne's financial structure and understand the extent to which Bio Techne's operations depend on creditor capital.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bio Techne Corp (TECH) is traded on NASDAQ Exchange in USA and employs 3,100 people. Bio Techne is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.45 B. Bio Techne Corp conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 156.45 M outstanding shares of which 10.36 M shares are at this time shorted by private and institutional investors with about 5.64 trading days to cover.
Bio Techne Corp currently holds about 247.03 M in cash with 287.56 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.3.
Check Bio Techne Probability Of Bankruptcy
Ownership AllocationBio Techne holds a total of 156.45 Million outstanding shares. The majority of Bio Techne Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bio Techne Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bio Techne. Please pay attention to any change in the institutional holdings of Bio Techne Corp as this could imply that something significant has changed or is about to change at the company. Also note that nearly one thousand five hundred sixty-five invesors are currently shorting Bio Techne expressing very little confidence in its future performance.
Check Bio Ownership Details
Bio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Mairs & Power Inc | 2025-06-30 | 2.7 M | |
| Champlain Investment Partners, Llc | 2025-06-30 | 2.7 M | |
| Mackenzie Investments | 2025-06-30 | 2.6 M | |
| Neuberger Berman Group Llc | 2025-06-30 | 2.5 M | |
| Citadel Advisors Llc | 2025-06-30 | 2.5 M | |
| Sumitomo Mitsui Trust Group Inc | 2025-06-30 | 2.3 M | |
| Rgm Capital Llc | 2025-06-30 | 2.2 M | |
| Bank Of New York Mellon Corp | 2025-06-30 | 1.9 M | |
| Norges Bank | 2025-06-30 | 1.9 M | |
| Vanguard Group Inc | 2025-06-30 | 18.4 M | |
| Blackrock Inc | 2025-06-30 | 12.2 M |
Bio Techne Historical Income Statement
Bio Stock Against Markets
Bio Techne Corporate Management
| Lynne Hohlfeld | Senior Division | Profile | |
| Steven Crouse | Senior Division | Profile | |
| Gerry Andros | Vice Marketing | Profile | |
| Bernie Andruss | Senior Division | Profile | |
| Kim Kelderman | Pres Genomics | Profile | |
| Dylan Malayter | Senior Division | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is there potential for Life Sciences Tools & Services market expansion? Will Bio introduce new products? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.091 | Dividend Share 0.16 | Earnings Share 0.53 | Revenue Per Share | Quarterly Revenue Growth (0) |
Understanding Bio Techne Corp requires distinguishing between market price and book value, where the latter reflects Bio's accounting equity. The concept of intrinsic value - what Bio Techne's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Bio Techne's price substantially above or below its fundamental value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Bio Techne's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.